177 related articles for article (PubMed ID: 10383765)
1. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy.
Wang P; Brobey RK; Horii T; Sims PF; Hyde JE
Mol Microbiol; 1999 Jun; 32(6):1254-62. PubMed ID: 10383765
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of dihydrofolate reductase and dihydropteroate synthetase genotypes that confer resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum in Haiti.
Carter TE; Warner M; Mulligan CJ; Existe A; Victor YS; Memnon G; Boncy J; Oscar R; Fukuda MM; Okech BA
Malar J; 2012 Aug; 11():275. PubMed ID: 22889367
[TBL] [Abstract][Full Text] [Related]
3. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization.
Wang P; Read M; Sims PF; Hyde JE
Mol Microbiol; 1997 Mar; 23(5):979-86. PubMed ID: 9076734
[TBL] [Abstract][Full Text] [Related]
4. Ordered accumulation of mutations conferring resistance to sulfadoxine-pyrimethamine in the Plasmodium falciparum parasite.
Mita T; Ohashi J; Venkatesan M; Marma AS; Nakamura M; Plowe CV; Tanabe K
J Infect Dis; 2014 Jan; 209(1):130-9. PubMed ID: 23922363
[TBL] [Abstract][Full Text] [Related]
5. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins.
Wang P; Lee CS; Bayoumi R; Djimde A; Doumbo O; Swedberg G; Dao LD; Mshinda H; Tanner M; Watkins WM; Sims PF; Hyde JE
Mol Biochem Parasitol; 1997 Nov; 89(2):161-77. PubMed ID: 9364963
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana.
Marks F; Evans J; Meyer CG; Browne EN; Flessner C; von Kalckreuth V; Eggelte TA; Horstmann RD; May J
Antimicrob Agents Chemother; 2005 Mar; 49(3):1101-5. PubMed ID: 15728909
[TBL] [Abstract][Full Text] [Related]
7. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole.
Khalil I; Rønn AM; Alifrangis M; Gabar HA; Satti GM; Bygbjerg IC
Am J Trop Med Hyg; 2003 May; 68(5):586-9. PubMed ID: 12812351
[TBL] [Abstract][Full Text] [Related]
8. Geographical spread and structural basis of sulfadoxine-pyrimethamine drug-resistant malaria parasites.
Chaturvedi R; Chhibber-Goel J; Verma I; Gopinathan S; Parvez S; Sharma A
Int J Parasitol; 2021 Jun; 51(7):505-525. PubMed ID: 33775670
[TBL] [Abstract][Full Text] [Related]
9. Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome.
Khalil I; Alifrangis M; Rønn AM; Gabar HA; Jelinek T; Satti GM; Bygbjerg IC
Am J Trop Med Hyg; 2002 Sep; 67(3):225-9. PubMed ID: 12408659
[TBL] [Abstract][Full Text] [Related]
10. Transfection studies to explore essential folate metabolism and antifolate drug synergy in the human malaria parasite Plasmodium falciparum.
Wang P; Wang Q; Aspinall TV; Sims PF; Hyde JE
Mol Microbiol; 2004 Mar; 51(5):1425-38. PubMed ID: 14982635
[TBL] [Abstract][Full Text] [Related]
11. Genetic and metabolic analysis of folate salvage in the human malaria parasite Plasmodium falciparum.
Wang P; Nirmalan N; Wang Q; Sims PF; Hyde JE
Mol Biochem Parasitol; 2004 May; 135(1):77-87. PubMed ID: 15287589
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania.
Mbugi EV; Mutayoba BM; Malisa AL; Balthazary ST; Nyambo TB; Mshinda H
Malar J; 2006 Oct; 5():94. PubMed ID: 17076899
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity.
Alifrangis M; Enosse S; Khalil IF; Tarimo DS; Lemnge MM; Thompson R; Bygbjerg IC; Rønn AM
Am J Trop Med Hyg; 2003 Dec; 69(6):601-6. PubMed ID: 14740875
[TBL] [Abstract][Full Text] [Related]
14. Detection of drug resistance markers for chloroquine and pyrimethamine-sulfadoxine in Jazan area, Saudi Arabia using PCR and restriction digestion.
Al Harthi SA
J Egypt Soc Parasitol; 2007 Apr; 37(1):17-30. PubMed ID: 17580565
[TBL] [Abstract][Full Text] [Related]
15. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
Plowe CV; Cortese JF; Djimde A; Nwanyanwu OC; Watkins WM; Winstanley PA; Estrada-Franco JG; Mollinedo RE; Avila JC; Cespedes JL; Carter D; Doumbo OK
J Infect Dis; 1997 Dec; 176(6):1590-6. PubMed ID: 9395372
[TBL] [Abstract][Full Text] [Related]
16. Sulfadoxine-pyrimethamine susceptibilities and analysis of the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum isolates from Côte d'Ivoire.
Djaman JA; Mazabraud A; Basco L
Ann Trop Med Parasitol; 2007 Mar; 101(2):103-12. PubMed ID: 17316496
[TBL] [Abstract][Full Text] [Related]
17. Source of drug resistant Plasmodium falciparum in a potential malaria elimination site in Saudi Arabia.
Al-Farsi HM; Al-Hashami ZS; Bin Dajem SM; Al-Sheikh AA; Al-Qahtani A; Beja-Pereira A; Idris MA; Babiker HA
Infect Genet Evol; 2012 Aug; 12(6):1253-9. PubMed ID: 22709478
[TBL] [Abstract][Full Text] [Related]
18. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
A-Elbasit IE; Alifrangis M; Khalil IF; Bygbjerg IC; Masuadi EM; Elbashir MI; Giha HA
Malar J; 2007 Aug; 6():108. PubMed ID: 17686173
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
Happi CT; Gbotosho GO; Folarin OA; Akinboye DO; Yusuf BO; Ebong OO; Sowunmi A; Kyle DE; Milhous W; Wirth DF; Oduola AM
Acta Trop; 2005 Sep; 95(3):183-93. PubMed ID: 16023986
[TBL] [Abstract][Full Text] [Related]
20. Use of bacterial surrogates as a tool to explore antimalarial drug interaction: Synergism between inhibitors of malarial dihydrofolate reductase and dihydropteroate synthase.
Talawanich Y; Kamchonwongpaisan S; Sirawaraporn W; Yuthavong Y
Acta Trop; 2015 Sep; 149():64-9. PubMed ID: 25997881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]